Celltrion awaits market authorization of Remsima from 52 countries

Published: 2012-10-25 06:58:00

Updated: 2012-10-25 06:58:00

Celltrion, a local biopharmaceutical company, said Monday that it has awaited approval of Remsima from 52 countries as well as the European Medicines Agency (EMA).

Remsima is a biosimilar version of U.S. Merck’s Remicade, a globally renowned medication for rheumatoid arthritis.

By the end ...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK